What We Do
We are dedicated to improving the lives of everyone affected by long-term conditions – patients, their caregivers and loved ones as well as healthcare professionals.

Our services provide synergistic strategies and tools for pharma and biotech executives across drug development and patient engagement. We also are happy to help with plugging in behaviour change expertise for partner agencies.
COA Strategies
We work with pharma, biotech, and device companies to incorporate the patient voice early in the drug development timeline, from pre-Phase 1 through to Phase 3 clinical trials.
We advise clients on the selection and use of traditional and digital COA (clinical outcomes assessment) measures to ensure that endpoints in pivotal trials reflect the symptoms and impacts relevant to patients/caregivers and are measured in a robust and interpretable way. Importantly, we understand and anticipate the regulatory point-of-view, so clients are set up for regulatory success downstream.
Some of the people we’ve helped include:
Evidence-Based Insights
We offer a science-led approach to exploring patient, caregiver and healthcare professional experiences and perceptions of disease and treatment.
Our approach is fitted to your needs, and can include review of existing materials, literature review (including systematic review if required), qualitative and quantitative studies or market research, central or local IRB/ethics approval, and dissemination support (including conference abstracts and development of manuscripts for peer-reviewed publication).
Some of the people we’ve helped include:
Behaviour Change Programmes
Our scientists tap into a broad toolbox of hundreds of behaviour change techniques to identify and address barriers and beliefs for improved health. Each programme is customised to reflect the patient voice and to support the patient’s journey as they navigate a chronic condition.
We ground our work in psychological theory, and blend evidence review with stakeholder co-creation to create innovative behaviour change strategies and content. Importantly, we don’t work in a bubble – our academic expertise is coupled with an understanding of the regulatory and commercial landscape in each market.
Some of the people we’ve helped include:
Digital Products and Services
Our increasingly digital healthcare world has created a new dynamic in both how clinical trials are run and how patient support is envisaged, shifting greater responsibility on patients to manage their health with web-based platforms, on-demand tools, and wearable devices. It’s critical for these digital services to reflect an authentic patient experience to drive meaningful engagement.
Whether it’s developing evidence-based content for a digital support programme or consulting on digital COA (clinical outcomes assessment) end points, we prioritize the patient voice.